Facebook Twitter Instagram linkedin YouTube

Doctor Profile - Dr. T.S Ganesan

Dr. T.S Ganesan



Area(s) of Specialization:

Medical Oncology Head, Cancer Biology Laboratory

Consultation days:

Tuesdays, Friday.

Consultation Time:

8:00 pm to 1:00 pm

For Appointment, Call:

044 - 45928548 EXT: 316/3410


Development and invitro characterisation of an induced pluripotent stem cell model of ovarian cancer. S. Bindhya. et al, (2021), Int J Biochem Cell Biol, (In Press)

Oncogenes in high grade serous adenocarcinoma of the ovary. Pacharla Manasa. et al, (2020), Genes Cancer, 11, 122-136

The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary. Smarakan Sneha. et al, (2020), Cell Oncol, 43, 601-616.

ALDH1A1+ ovarian cancer stem cells co-expressing surface markers CD24, EPHA1 and CD9 form tumours in vivo. Rohit P Nagare. et al, (2020), Exp Cell Res, 392.

Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary. Syama Krishnapriya. et al, (2019), Angiogenesis, 22, 441-455.

Induced Pluripotent Stem Cells: A New Strategy to Model Human Cancer. Bindhya S. et al, (2019), Int J Biochem Cell Biol, 107,62-68.

A systematic understanding of signaling by ErbB2 in cancer using phosphoproteomics. C.Sidhanth. et al, (2018), Biochem Cell Biol, 96, 295- 305.

Therapeutic antibodies against cancer stem cells: a promising approach. Smarakan Sneha. et al, (2017), Cancer Immunol Immunother, 66, 1383-1398


First, the studies of cancer stem cells is to understand how cancer develops in general. The aim is to identify and characterize these cancer stem cells and study their properties. If the cancer stem cell hypothesis is correct then targeting these cells will be very important for the management of patients with cancer. We have focused on serous ovarian cancer for a comprehensive analysis of cancer stem cells.

The second area of research is to try and understand signaling pathways, which are commonly affected in cancer. Usually, cells are stimulated by signaling through receptors which are on the surface of the cells. These are increased in expression or amplified at the gene level in cancer. This has led to the discovery of specific small molecule inhibitors which target type I and type III receptors tyrosine kinases. We have chosen a mass spectrometry based approach and identified several novel phosphoproteins in the ErbB2 signaling pathway

The third area of research is to identify oncogenes and tumour suppressor genes important in the pathogenesis of ovarian cancer. We have identified by a novel bioinformatics approach RNF144B and PPP2R2A and are identifying their role in ovarian cancer.

Other Consultants in Medical Oncology

Medical Oncology

Direct : 044 - 45928548 (8am-4pm) Board: 044-45928500

Ext.no. 316